Schlumberger Ltd. (SLB) Pops 5.75% for January 28

Equities Staff |

One of the S&P 500’s big winners for Thursday January 28 was Schlumberger Ltd. (SLB) as the company’s stock climbed 5.75% to $69.32 on volume of 12.89 million shares.

The stock opened at $68.23 and saw an intraday low of $67.24 and an intraday high of $69.47. All told, the day saw a per-share gain of $3.77. The stock’s average daily volume of 9.08 million and 1.26 billion shares outstanding. Schlumberger Ltd. now has a 50-day SMA is $70.42 and 200-day SMA is $78.99, and it has a 52-week high of $95.13 and a 52-week low of $59.60.

Schlumberger Ltd is a supplier of technology, integrated project management and information solutions to customers working in the oil and gas industry. Its business segments are Reservoir Characterization Group, Drilling Group and Production Group.

Based out of Houston, TX, Schlumberger Ltd. has 0 employees and, after today’s trading, reached a market cap of $87.42 billion. Its P/S ratio is n/a, P/B ratio is 2.3, and P/FCF ratio is 30.1.

For a complete fundamental analysis analysis of Schlumberger Ltd., check out’s Stock Valuation Analysis report for SLB. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…